Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.30 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424215 | 0.98 | ALDH1A1 (0.60) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16424382 | 0.98 | ALDH1A1 (0.60) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16424451 | 0.98 | ALDH1A1 (0.60) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16390481 | 0.95 | SMN1; SMN2 (0.58) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16423873 | 0.89 | ALDH1A1 (0.70) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16423572 | 0.89 | ALDH1A1 (0.60) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16423840 | 0.89 | ALDH1A1 (0.65) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16424471 | 0.88 | SMN1; SMN2 (0.52) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16423614 | 0.88 | ALDH1A1 (0.63) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 | |
| SCHEMBL16423888 | 0.88 | ALDH1A1 (0.68) | TSHRALDH1A1TDP1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226924-B2 | Methods of treating or preventing neuropathic pain | TORAY INDUSTRIES, INC. (JP) | 2016-01-05 | — | — | US | disclosed |
| US-20150105430-A1 | METHODS OF TREATING OR PREVENTING NEUROPATHIC PAIN | TORAY INDUSTREIS INC (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105430-A1 | METHODS OF TREATING OR PREVENTING NEUROPATHIC PAIN | CACNB2, CACNG2, SCN2A | TSHR 4075/4885ALDH1A1 1427/4885TDP1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.